News

A 30 million euro call for research in neurodegenerative disease was recently announced by the EU Joint Programme – Neurodegenerative Disease Research (JPND). The program will receive an additional 10 million in funding from the Horizon 2020 framework program for research and innovation of the European Union. Alzheimer’s, Parkinson’s and other…

The U.S. Food and Drug Administration (FDA) has granted Arjuna Natural Extracts Ltd. a U.S. patent for the company’s turmeric extract formulation, BCM-95 Curcumin, which is expected to become a treatment for patients suffering from Alzheimer’s disease. The patent number 8859020 describes the drugs’s combination of beneficial curcuminoids and turmeric…

The Neurodegeneration Medicines Acceleration Program (Neuro-MAP) led by MRC Technology is a non-profit organization that brings together promising drug projects for brain diseases like Parkinson’s and Alzheimer’s that have stalled due to lack of support with funding organizations. Their goal is to revive these projects by helping scientists continue their…

A Stanford University School of Medicine study recently published in the Journal of Clinical Investigation, entitled “Prostaglandin signaling suppresses beneficial microglial function in Alzheimer’s disease models,” indicate that microglia impairment may be under the cause of Alzheimer’s disease. The cause of Alzheimer’s disease (AD) is…

Biotech industry veteran Tony Coles, M.D. has launched a new startup — Cambridge, Massachusetts-based Yumanity Therapeutics. Founded in December 2014, the new company’s central focus is on drug discovery for diseases caused by a DNA anomaly called “protein misfolding.” Yumanity Therapeutics’ founders include by Dr. Coles, who is…

A new study on Dementia with Lewy bodies (DLB) and Corticobasal Syndrome (CBS) entitled “Differentiating between visual hallucination-free dementia with Lewy bodies and corticobasal syndrome on the basis of neuropsychology and perfusion single-photon emission computed tomography” was published in Alzheimer’s Research & Therapy by Michael R Misch, part…

A new study is now enrolling and accepting volunteers to investigate the potential of a new drug to slow the devastating effects of Alzheimer’s disease on patients’ memory and physical activity. Eligible participants include men and women with ages between 55 to 85 years old suffering from mild to severe Alzheimer’s.

A study entitled “Enhancing dentate gyrus function with dietary flavanols improves cognition in older adults,” published this month in Nature Neuroscience, found that a cocoa flavanol containing diet ameliorates cognitive function in older people. The dentate gyrus (DG) is a region in the hippocampal formation whose function…

Scientists at the University of Illinois have created an exciting new method for examining how proteins change their shape right inside cells, using fluorescent markers and a specialized microscope. They recently published their work in the December 1st issue of the journal Public Library of Science One (PLoS…

Recently, a new study presented at the Annual Meeting of the Radiological Society of North America (RSNA) showed that in brains of patients affected with Alzheimer’s disease, changes in brain connections can be visualized by Magnetic resonance imaging (MRI). Alzheimer’s disease is currently estimated to affect approximately 5 million…